{"id":"W2624483458","doi":"10.1200/jco.2017.35.15_suppl.1008","title":"Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Tolerability; Adverse effect; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001387403,0.00106541,0.001023321,0.0003052607,0.0003672986,0.0007352284,0.0007154022,0.0009233939,0.006916672],"category_scores_gemma":[0.0008329965,0.0005178364,0.0007331395,0.0002599561,0.0003440869,0.0007028747,0.0003975241,0.002142651,0.001571004],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009278782,"about_ca_system_score_gemma":0.001573493,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001162804,"about_ca_topic_score_gemma":0.003028159,"domain_scores_codex":[0.9997948,0.00008196306,0.000009813469,0.00004501312,0.00002593585,0.00004255124],"domain_scores_gemma":[0.9995781,0.00004417607,0.00008408078,0.00003692563,0.00004249709,0.0002142311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6875057,0.09872083,0.01799152,0.001368779,0.002068272,0.0005652347,0.0003524714,0.002588303,0.06385829,0.0005477184,0.02396511,0.1004677],"study_design_scores_gemma":[0.6720411,0.2827573,0.02521497,0.00009543377,0.0009486533,0.001041986,0.0001061774,0.001989817,0.004389066,0.0004760753,0.01089864,0.00004081261],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9776772,0.002292686,0.0009379467,0.000637755,0.000147224,0.006709813,0.00724816,0.0001507377,0.004198525],"genre_scores_gemma":[0.9654267,0.002386781,0.003538841,0.001817307,0.0001861295,0.006889723,0.01181693,0.00006745743,0.007870145],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006916672,"threshold_uncertainty_score":0.02313858,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1507263643277155,"score_gpt":0.524890833082499,"score_spread":0.3741644687547835,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}